SMMT · XBRL financial data

Summit Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SMMT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1	2	1	0	0	—
Research and development	53	85	52	59	—	—
General and administrative	19	24	27	30	61	557
Total operating expenses	73	109	87	611	226	1,094
Other operating income (expense)	—	—	14	1	0	—
Operating income (loss)	(53)	(86)	(72)	(610)	(226)	—
Interest income	0	0	2	—	—	—
Interest expense	0	0	4	16	9	0
Other income (expense)	—	(0)	0	(0)	0	(0)
Income tax expense (benefit)	(0)	0	—	0	0	0
Net income (loss)	(53)	(89)	(79)	(615)	(221)	(1,080)
Earnings per share, basic USD per share	(0.76)	(0.96)	(0.41)	(0.99)	(0.31)	(1.44)
Earnings per share, diluted USD per share	(0.76)	(0.96)	(0.41)	(0.99)	(0.31)	(1.44)
Weighted average shares, basic millions of shares	70	92	193	620	719	748
Weighted average shares, diluted millions of shares	70	92	193	620	719	748

† Share count changed about 7x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SMMT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	66	72	349	71	105	225
Short-term investments	—	—	0	115	307	488
Accounts receivable	0	1	0	0	—	—
Prepaid and other current assets	—	—	—	3	11	7
Total current assets	88	97	657	190	424	720
Property and equipment, net	1	1	1	0	0	1
Right-of-use asset	1	3	4	6	7	21
Goodwill	2	2	2	2	2	2
Total assets	102	113	664	203	436	751
Accounts payable	6	4	0	3	5	20
Accrued liabilities	4	7	11	9	20	32
Total current liabilities	20	26	39	20	42	73
Lease liability, non-current	0	2	3	3	3	18
Total liabilities	23	30	538	125	47	92
Accumulated deficit	(211)	(300)	(378)	(993)	(1,215)	(2,294)
Total stockholders' equity	79	83	127	78	389	659
Total liabilities and equity	102	113	664	203	436	751
Common shares outstanding (cover page) millions of shares	83	98	698	702	738	775

† Share count changed about 7x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SMMT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(53)	(89)	(79)	(615)	(221)	(1,080)
Stock-based compensation	2	13	12	14	51	732
Net cash from operating activities	(48)	(73)	(42)	(77)	(142)	(323)
Purchases of property and equipment	0	0	1	0	0	1
Net cash from investing activities	(0)	(0)	(1)	(588)	(205)	(174)
Proceeds from issuing common stock	50	75	100	105	—	—
Dividends paid	0	—	—	—	—	—
Net cash from financing activities	51	78	620	87	381	618
Net change in cash	3	5	577	(577)	34	120

† Share count changed about 7x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.